Dr. Kai from Safety BU to Deliver an Oral Presentation at the 9th Drug Discovery & Lead Optimization Conference
Dr. Kiyonori Kai from the Safety Business Unit, …
xFOREST Therapeutics and Axcelead DDP Launch Joint Research Initiative on RNA Structure-Targeted Small Molecule Drug Discovery
Kyoto and Kanagawa, Japan, September 18, 2025 – …
Researcher Tanaka and Ogawa from Pharmacology BU to Present at a symposium hosted by CIEM
Our researcher, Hiroshi Tanaka and Masahiro Ogawa from …
Researcher Tabata from Pharmacology BU to Present a Poster at the 84th Annual Meeting of the Japanese Cancer Association
Our researcher, Ryotaro Tabata from the Pharmacology Business …
Researcher Unno from Pharmacology BU to Present a Poster at the 84th Annual Meeting of the Japanese Cancer Association
Our researcher, Satoko Unno from the Pharmacology Business …
Diverse Approaches to New Chemical Modalities -Challenging the Undruggable Targets beyond Conventional Small Molecule Drug Discovery-
In recent years, targeted drug discovery has become increasingly challenging, making it essential to explore optimal modalities beyond traditional small molecules to develop new drugs successfully.
LSX USA Congress 2025
Boston, MA
Nissan Chemical and Axcelead DDP Enter into Business Partnership to Support Drug Discovery Research for RNA Therapeutics
Tokyo and Kanagawa, Japan, July 18, 2025 — …
PRD Therapeutics Initiates First-in-Human Clinical Trial of SOAT2-Selective Inhibitor ‘PRD001’ — Axcelead DDP Provides Comprehensive Non-Clinical Development Support —
PRD Therapeutics, Inc. (“PRD Therapeutics”), a clinical stage …